Subject: Cell Phone Users At Risk for Brain Cancer,... (DeRosa)..
Date: Thu, 4 May 2000 162917 -0500 (CDT)
From: "Roy L. Beavers"
To: emfguru
--------------------------------------------------
........Folks, I believe this is a recent follow-up on some research
that is a couple years old..... Without going to the references
(whixh I have not yet) I wonder about how much of it is actually based
on new data.....??
Roy Beavers (EMFguru)
roy@emfguru.com
.....It is better to light a single candle than to curse the darkness.....
NEW!!! Website... http://emfguru.com
...................People are more important than profits.................
---------- Forwarded message ----------
Date: Thu, 4 May 2000 16:31:53 EDT
From: Light540@aol.com
To: rbeavers@llion.org
Subject: Re: Cell Phone Users Still At Risk for Brain Cancer,...
Regards,
Elena
Cell Phone Users Still At Risk for Brain Cancer, According to Swedish
Medical Researchers
NEW YORK, N.Y.--(BW HealthWire)--May 4, 2000--
Peer-Reviewed Article on Medscape General Medicine Points
to Higher Risk for Analog Phones
With worldwide cellular phone use rising exponentially, a team of Swedish
medical investigators is raising renewed concerns about links between brain
tumors and the phones in a new, peer-reviewed article to be posted today on
Medscape General Medicine, (MedGenMed, www.medscape.com/journal/MedGenMed),
the online general medical journal.
In the report, "Case-Control Study on Radiological Work, Medical X-ray
Investigations and Use of Cellular Telephones as Risk Factors for Brain
Tumors," the Swedish team investigated localization of the brain tumors
since handheld cell phones increase the exposure of microwaves to the
side of the brain corresponding to the side of the head most favored by
cell phone users.
Statistical analysis indicated an increase in associated risk for brain
tumors in the anatomical areas - i.e., temporal, temporoparietal and
occipital lobes of the brain -- that received the highest doses of
microwaves. The risk from cell phones was significantly increased when
adjustment was made for other risk factors in the study (laboratory work
and medical x-ray investigations of the head and neck). The article also
points out that all but one of the 13 individuals with malignant or
benign tumors within exposed anatomical areas of the brain relied on the
older analog technology with greater power output. The complete report
will be available to the public at
http://www.medscape.com/MedGenMed/braintumors.
The study, conducted over a two-year period in two separate regions of
Sweden, evaluated a total of 233 patient cases with verified brain tumors.
Each of these patient cases was matched to two controls, or healthy
subjects (466 in total), based on similar sex, age, and geography. Eight
of these 233 patients had recurrent brain tumors and were excluded from
the study together with their matched controls. The cases and controls
were evaluated for exposure to a variety of possible cancer risks through
questionnaires and additional telephone interviews. The statistical
analysis was based on answers from 209 cases and 425 controls. Some of
the other risks examined in this study included exposure to radiation,
electromagnetic fields or video displays, exposure to various chemical
agents including pesticides, exposure to the sweetener aspartame, and
risk by occupation. The study was supported by grants from Cancer- och
Allergifonden, the Swedish Medical Research
Council and Orebro Cancer Fund.
Dr. George D. Lundberg, Editor-in-Chief of MedGenMed and its parent
company, Medscape, Inc., said of the article, "The study reaffirms that
this issue requires further investigation, in spite of recent reports
downplaying the association between cell phone use and brain tumors, and
the lower-power output associated with newer digital phones . With the
proliferation of cell phones -- and the fact that many older higher-power
output phones are still in use -- it is important to adequately assess
the risks in larger, ongoing studies."
Authors of the report are Lennart Hardell, MD, PhD, Department of
Oncology, Orebro Medical Center; Asa Nasman, MSc, Department of Oncology,
Orebro Medical Center; Anneli Pahlson, MD, Department of Neurology,
Orebro Medical Center; and Arne Hallquist, MD, PhD, Department of
Oncology, Karolinska Institute and Stockholms Sjukhem, Stockholm, Sweden.
Journalists may reach Dr. Hardell at: phone + 46 19 602 15 46, fax + 46
19 10 17 68, e-mail: lennart.hardell@orebroll.se.
Archive provided courtesy of WaveGuide, http://www.wave-guide.org
Reprinted with permission of Roy Beavers, http://www.emfguru.com